Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | Director | June 22, 2026 | June 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Pharma, Inc.
Report date June 22, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,981 |
Reported balance
After 2026-06-22 transaction · row 1
1 source rowRow 1 · 2026-06-22 · Grant · Acquired 3,990 · Balance 20,981 F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.92 · Expires 2036-06-21 | Direct | 5,277 |
Reported balance
After 2026-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-22 · Grant · Acquired 5,277 · Balance 5,277 F3: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2026 Filed Jun 24, 2026 22:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 5,277 | $0.00 Strike: $68.92 | $0.00 |
DisclosureSEC source: 0001470831-26-000631 · wk-form4_1782338755.xml · derivative · entry 2 DANIELS RONALD J · CIK 0001164475 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,277 Underlying: Common Stock · 5,277 shares Expires 2036-06-21 F3 · derivative.exercise_date: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 22:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantCommon Stock | 3,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000631 · wk-form4_1782338755.xml · nonDerivative · entry 1 DANIELS RONALD J · CIK 0001164475 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,981 F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 23:03 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (Right to Buy) · Derivative | 61,031 | $0.00 Strike: $34.65 | $0.00 |
DisclosureSEC source: 0001470831-25-000297 · wk-form4_1762556613.xml · derivative · entry 3 DANIELS RONALD J · CIK 0001164475 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,523 Underlying: Common Stock · 61,031 shares Expires 2030-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to this option vested and became exercisable in three annual installments from February 12, 2020 to February 12, 2023. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 23:03 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 61,031 | $63.72 | $3,888,999.07 |
DisclosureSEC source: 0001470831-25-000297 · wk-form4_1762556613.xml · nonDerivative · entry 2 DANIELS RONALD J · CIK 0001164475 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,991 F1 · price: Represents the weighted average sale price of the shares sold from $63.70 to $63.88 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 23:03 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 61,031 | $34.65 | $2,114,724.15 |
DisclosureSEC source: 0001470831-25-000297 · wk-form4_1762556613.xml · nonDerivative · entry 1 DANIELS RONALD J · CIK 0001164475 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,022 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 23:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 8,425 | $0.00 Strike: $41.73 | $0.00 |
DisclosureSEC source: 0000950170-25-089666 · ownership.xml · derivative · entry 2 DANIELS RONALD J · CIK 0001164475 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,425 Underlying: Common Stock · 8,425 shares Expires 2035-06-19 F3 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 23:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantCommon Stock | 6,589 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-089666 · ownership.xml · nonDerivative · entry 1 DANIELS RONALD J · CIK 0001164475 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,991 F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 21, 2024 Filed Jun 25, 2024 21:36 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 26,014 | $0.00 Strike: $27.36 | $0.00 |
DisclosureSEC source: 0000950170-24-077442 · ownership.xml · derivative · entry 1 DANIELS RONALD J · CIK 0001164475 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,014 Underlying: Common Stock · 26,014 shares Expires 2034-06-20 F1 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 21, 2024, such that all of the underlying shares will be vested on June 21, 2027, subject to the Reporting Person's continued service on the board of directors of the Issuer. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:17 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 51,501 | $0.00 Strike: $16.75 | $0.00 |
DisclosureSEC source: 0001209191-23-039361 · doc4.xml · derivative · entry 1 DANIELS RONALD J · CIK 0001164475 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,501 Underlying: Common Stock · 51,501 shares Expires 2033-06-21 F1 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 20:27 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 104,921 | $0.00 Strike: $8.45 | $0.00 |
DisclosureSEC source: 0001209191-22-039238 · doc4.xml · derivative · entry 1 DANIELS RONALD J · CIK 0001164475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,921 Underlying: Common Stock · 104,921 shares Expires 2032-06-22 F1 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document |
| December 30, 2021 Filed Dec 31, 2021 01:17 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | PurchaseCommon Stock | 10,402 | $14.34 | $149,164.68 |
DisclosureSEC source: 0000899243-21-050130 · doc4.xml · nonDerivative · entry 3 DANIELS RONALD J · CIK 0001164475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,402 Read SEC document |
| December 28, 2021 Filed Dec 31, 2021 01:17 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 11,745 | $12.80 | $150,336.00 |
DisclosureSEC source: 0000899243-21-050130 · doc4.xml · nonDerivative · entry 2 DANIELS RONALD J · CIK 0001164475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: The Reporting Person realized short-swing profits under Section 16(b) of the Securities Exchange Act of 1934, as amended, as a result of the purchase and sale of the Issuer's common stock on December 28, 2021 reported herein. The Reporting Person has agreed to voluntarily disgorge to the Issuer all short-swing profits realized by the Reporting Person from such transactions. F3 · price: Represents the weighted average sale price of the shares sold from $12.79 to $12.82 per share. Read SEC document |
| December 28, 2021 Filed Dec 31, 2021 01:17 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | PurchaseCommon Stock | 11,745 | $12.73 | $149,513.85 |
DisclosureSEC source: 0000899243-21-050130 · doc4.xml · nonDerivative · entry 1 DANIELS RONALD J · CIK 0001164475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,745 F1 · shares: The Reporting Person realized short-swing profits under Section 16(b) of the Securities Exchange Act of 1934, as amended, as a result of the purchase and sale of the Issuer's common stock on December 28, 2021 reported herein. The Reporting Person has agreed to voluntarily disgorge to the Issuer all short-swing profits realized by the Reporting Person from such transactions. F2 · price: Represents the weighted average sale price of the shares sold from $12.7275 to $12.73 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 2 and 3. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 23:15 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 38,895 | $0.00 Strike: $62.63 | $0.00 |
DisclosureSEC source: 0000899243-21-025397 · doc4.xml · derivative · entry 1 DANIELS RONALD J · CIK 0001164475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,895 Underlying: Common Stock · 38,895 shares Expires 2031-06-16 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in three annual installments after June 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date. Read SEC document |
| February 12, 2020 Filed Feb 15, 2020 01:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 91,554 | $0.00 Strike: $34.65 | $0.00 |
DisclosureSEC source: 0000899243-20-004766 · doc4.xml · derivative · entry 1 DANIELS RONALD J · CIK 0001164475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,554 Underlying: Common Stock · 91,554 shares Expires 2030-02-11 F1 · derivative.exercise_date: The shares subject to this option vest and become exercisable in three annual installments after February 12, 2020, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.